Canna~Fangled Abstracts

Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis

By March 24, 2024March 25th, 2024No Comments


doi: 10.1016/j.drugalcdep.2024.111267.

Online ahead of print.
Affiliations 

Abstract

Background: Cannabis contains hundreds of chemical constituents beyond delta-9-tetrahydrocannabinol (THC), which is believed to drive most of its acute pharmacodynamic effects. The entourage effect theory asserts that non-THC constituents can impact acute cannabis effects, but few empirical studies have systematically evaluated this theory in humans. This study assessed whether the cannabis terpenoid d-limonene mitigates the acute anxiogenic effects of THC.

Methods: Twenty healthy adults completed nine, double-blind outpatient sessions in which they inhaled vaporized THC alone (15mg or 30mg), d-limonene alone (1mg or 5mg), the same doses of THC and d-limonene together, or placebo; a subset of participants (n=12) completed a tenth session in which 30mg THC+15mg d-limonene was administered. Outcomes included subjective drug effects, cognitive/psychomotor performance, vital signs, and plasma THC and d-limonene concentrations.

Results: When d-limonene was administered alone, pharmacodynamic outcomes did not differ from placebo. Administration of 15mg and 30mg THC alone produced subjective, cognitive, and physiological effects typical of acute cannabis exposure. Ratings of anxiety-like subjective effects qualitatively decreased as d-limonene dose increased and concurrent administration of 30mg THC+15mg d-limonene significantly reduced ratings of “anxious/nervous” and “paranoid” compared with 30mg THC alone. Other pharmacodynamic effects were unchanged by d-limonene. D-limonene plasma concentrations were dose orderly, and concurrent administration of d-limonene did not alter THC pharmacokinetics.

Conclusions: D-limonene selectively attenuated THC-induced anxiogenic effects, suggesting this terpenoid could increase the therapeutic index of THC. Future research should determine whether this effect extends to oral dose formulations and evaluate the interactions between other cannabis terpenoids or cannabinoids and THC.

Keywords: Anxiety; Cannabis; D-limonene; THC.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Tory Spindle has served as a consultant for Canopy Health Innovations Inc. and has received research funding from Cultivate Biologics. Dr. Ryan Vandrey has served as a consultant or received honoraria from Mira1a Therapeutics Inc., Jazz Pharmaceuticals, Charlotte’s Web, Syqe Medical Ltd., and WebMD. Dr. Ethan Russo is the founder and CEO of CReDo Science and a scientific advisor to True Terpenes. A patent application (PCT/US2022/014296) has been submitted by Johns Hopkins University on behalf of Drs. Vandrey, Spindle, and Russo for the use of d-limonene to reduce THC-induced anxiety based on the data presented in this manuscript (the submission occurred after the trial had concluded and data was analyzed). Minimization of bias was ensured by posting of the trial on ClinicalTrials.gov before it commenced. The study was conceived and designed by Drs Vandrey and Russo. Drs. Spindle, Vandrey, and Zamarripa had full access to the data and worked together to write the first draft of the manuscript and each take responsibility for the integrity of the reported data. Remaining authors contributed to the manuscript by reviewing the completed draft and providing critical feedback and edits. Johns Hopkins played no role in the production of this manuscript. The remaining authors have no conflicts of interest to declare.

Similar articles

LinkOut – more resources


Leave a Reply